 Outlook Therapeutics, Inc. OTLK the Company, a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has taken action to improve the Companys balance sheet through two separate transactions. Effective December 23, 2019, with consent of the required holders of the Outlook Therapeutics warrants issued in April 2019 the Warrants in an underwritten public offering, the Company amended the Warrants to reduce the exercise price to 0.232 per warrant and allow for the immediate exercise of the Warrants. 